Literature DB >> 18269312

Protective immunity against neu-positive carcinomas elicited by electroporation of plasmids encoding decreasing fragments of rat neu extracellular domain.

Simona Rolla1, Cristina Marchini, Silvia Malinarich, Elena Quaglino, Stefania Lanzardo, Maura Montani, Manuela Iezzi, Mauro Angeletti, Giorgio Ramadori, Guido Forni, Federica Cavallo, Augusto Amici.   

Abstract

We have shown that electroporation of plasmid carrying extracellular and transmembrane domains (EC-TM plasmid) encoded by the rat neu oncogene triggers a protective immune response toward rat p185(neu)-positive tumors in both wild-type BALB/c mice and cancer-prone rat neu-transgenic BALB-neuT mice. To identify the critical fragments that confer this protective immunity, mice were electroporated with plasmids encoding the TM domain associated with decreasing fragments of the EC domain and the antitumor protection afforded, the titer of antibody, and cytotoxic T lymphocyte (CTL) activity elicited to Neu protein were evaluated. Plasmids encoding EC fragments shortened by 70 (EC1-TM plasmid), 150 (EC2-TM), 230 (EC3-TM), 310 (EC4-TM), and 390 (EC5-TM) NH(2)-terminal residues afforded effective protection. Plasmids encoding shorter truncated proteins were ineffective. When the immunogenic protein was retained in the cytoplasm (EC1-TM, EC2-TM, and EC5-TM), only a CTL response was elicited, whereas when it was also expressed on the membrane (EC4-TM) both CTLs and antibodies were induced. EC4-TM encoding a truncated protein with an EC portion of only 344 amino acids conferred protection on both BALB/c and BALB-neuT mice comparable to that of EC-TM.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18269312     DOI: 10.1089/hum.2006.196

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  11 in total

1.  NK cells control breast cancer and related cancer stem cell hematological spread.

Authors:  Rossana Tallerico; Laura Conti; Stefania Lanzardo; Rosa Sottile; Cinzia Garofalo; Arnika K Wagner; Maria H Johansson; Costanza Maria Cristiani; Klas Kärre; Ennio Carbone; Federica Cavallo
Journal:  Oncoimmunology       Date:  2017-02-23       Impact factor: 8.110

2.  Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent.

Authors:  Nafiseh Pakravan; Seyed Mahmoud Hashemi; Zuhair Mohammad Hassan
Journal:  Cell Stress Chaperones       Date:  2010-08-22       Impact factor: 3.667

3.  N-terminally fusion of Her2/neu to HSP70 decreases efficiency of Her2/neu DNA vaccine.

Authors:  Nafiseh Pakravan; Sara Soudi; Zuhair Mohammad Hassan
Journal:  Cell Stress Chaperones       Date:  2010-03-12       Impact factor: 3.667

4.  Combining human and rat sequences in her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity.

Authors:  Jennifer B Jacob; Elena Quaglino; Olga Radkevich-Brown; Richard F Jones; Marie P Piechocki; Joyce D Reyes; Amy Weise; Augusto Amici; Wei-Zen Wei
Journal:  Cancer Res       Date:  2010-01-01       Impact factor: 12.701

5.  DNA vaccination against oncoantigens: A promise.

Authors:  Manuela Iezzi; Elena Quaglino; Augusto Amici; Pier-Luigi Lollini; Guido Forni; Federica Cavallo
Journal:  Oncoimmunology       Date:  2012-05-01       Impact factor: 8.110

6.  A plant-expressed conjugate vaccine breaks CD4(+) tolerance and induces potent immunity against metastatic Her2(+) breast cancer.

Authors:  Warayut Chotprakaikiat; Alex Allen; Duc Bui-Minh; Elena Harden; Jantipa Jobsri; Federica Cavallo; Yuri Gleba; Freda K Stevenson; Christian Ottensmeier; Victor Klimyuk; Natalia Savelyeva
Journal:  Oncoimmunology       Date:  2016-04-22       Impact factor: 8.110

7.  Identification of relevant conformational epitopes on the HER2 oncoprotein by using Large Fragment Phage Display (LFPD).

Authors:  Federico Gabrielli; Roberto Salvi; Chiara Garulli; Cristina Kalogris; Serena Arima; Luca Tardella; Paolo Monaci; Serenella M Pupa; Elda Tagliabue; Maura Montani; Elena Quaglino; Lorenzo Stramucci; Claudia Curcio; Cristina Marchini; Augusto Amici
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

8.  Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive Cancers.

Authors:  Cristina Marchini; Cristina Kalogris; Chiara Garulli; Lucia Pietrella; Federico Gabrielli; Claudia Curcio; Elena Quaglino; Federica Cavallo; Augusto Amici
Journal:  Front Oncol       Date:  2013-05-14       Impact factor: 6.244

Review 9.  The Promise of Preventive Cancer Vaccines.

Authors:  Pier-Luigi Lollini; Federica Cavallo; Patrizia Nanni; Elena Quaglino
Journal:  Vaccines (Basel)       Date:  2015-06-17

Review 10.  Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns.

Authors:  Federica Riccardo; Aline Réal; Claudia Voena; Roberto Chiarle; Federica Cavallo; Giuseppina Barutello
Journal:  Vaccines (Basel)       Date:  2017-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.